For example, inhibitions of HDACs 1 and 2 [9], and 6 [27,38], as well as broader inhibitors of entire HDAC classes such as I and IIa [20,21,36], and IIb [50], have all been demonstrated recently to be neuroprotective in models of PD. This evidence concerns the gene HDAC9 and Parkinson disease.